Jazz Pharmaceuticals is committed to conducting our business with integrity and the pursuit of excellence in all that we do. Our management team and our Board of Directors are committed to honesty and compliance with all of the laws, rules, regulations and corporate policies that apply to our business, and we expect the same commitment from our employees, consultants, business partners and service providers. In order to ensure achievement of these objectives, Jazz Pharmaceuticals has established various methods of confidential communication for our employees, vendors and others to report suspected violations of laws, rules, regulations or company policies. Anonymous reporting is available through the following link and the toll-free numbers listed below.

To submit a report online, click here.

North America: 1-800-511-2034
Austria: 0800-291870
Belgium: 0800-77004
Canada (English): 1-800-511-2034
Canada (French): 1-855-350-9393
France: 0800-902500
Germany: 0800-1016582
Ireland: 1-800615403
Italy: 800-786907
Netherlands: 0800-0226174
Poland: 0-0-800-1211571
Portugal: 8008-12499
Spain: 900-991498
United Kingdom: 0800-032-8483
Jazz Pharmaceuticals’ Chief Compliance Officer is Robert McKague. The Chief Compliance Officer investigates reports of potential compliance issues, and helps educate employees about our compliance obligations. Reports can be made anonymously or confidentially.
WRITE: Jazz Pharmaceuticals plc
c/o Jazz Pharmaceuticals, Inc.
3180 Porter DrivePalo Alto, CA 94304
Attn: Chief Compliance Officer


On October 30, 2014, the Board of Directors of Jazz Pharmaceuticals plc amended and restated the Code of Conduct that applies to all Jazz Pharmaceuticals’ directors, officers and employees (“Covered Personnel”). The principal purpose of the amendment and restatement was to provide additional guidance to Covered Personnel regarding the available channels for reporting of possible legal or policy violations, to bring certain provisions of the Code of Conduct into conformity with certain legal requirements in jurisdictions outside the United States and other existing policies and procedures of the Company and to make certain other technical and administrative changes. The revisions to the Code of Conduct did not relate to or result in any waiver, explicit or implicit, of any provision of the Code of Conduct in effect prior to its amendment and restatement.